Efficacy of Cochleated Amphotericin B in Mouse and Human Mucocutaneous Candidiasis.
amphotericin B
chronic mucocutaneous candidiasis
cochleated
mouse model
mucosal candidiasis
phase 2 trial
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
19 07 2022
19 07 2022
Historique:
pubmed:
15
6
2022
medline:
22
7
2022
entrez:
14
6
2022
Statut:
ppublish
Résumé
Candida albicans causes debilitating, often azole-resistant, infections in patients with chronic mucocutaneous candidiasis (CMC). Amphotericin B (AMB) resistance is rare, but AMB use is limited by parenteral administration and nephrotoxicity. In this study, we evaluated cochleated AMB (CAMB), a new oral AMB formulation, in mouse models of oropharyngeal candidiasis (OPC) and vulvovaginal candidiasis (VVC) and in patients with azole-resistant CMC. OPC and VVC were modeled in
Identifiants
pubmed: 35699443
doi: 10.1128/aac.00308-22
pmc: PMC9295580
doi:
Substances chimiques
Antifungal Agents
0
Azoles
0
Amphotericin B
7XU7A7DROE
Banques de données
ClinicalTrials.gov
['NCT02629419']
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0030822Subventions
Organisme : NIAID NIH HHS
ID : K99 AI141622
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA AI001175
Pays : United States
Références
Antimicrob Agents Chemother. 1978 Aug;14(2):270-3
pubmed: 697352
mBio. 2021 Dec 21;12(6):e0287821
pubmed: 34724818
Clin Infect Dis. 1998 Sep;27(3):603-18
pubmed: 9770163
J Infect. 1991 Mar;22(2):201-4
pubmed: 2026897
Cell Host Microbe. 2016 Nov 9;20(5):606-617
pubmed: 27923704
Science. 2021 Jan 15;371(6526):
pubmed: 33446526
mBio. 2019 May 28;10(3):
pubmed: 31138748
J Vis Exp. 2011 Dec 08;(58):
pubmed: 22215135
Nature. 2008 Apr 10;452(7188):773-6
pubmed: 18337720
Curr Opin Allergy Clin Immunol. 2012 Dec;12(6):616-22
pubmed: 23026768
Mucosal Immunol. 2017 Sep;10(5):1335-1350
pubmed: 28176789
Microbes Infect. 2007 Apr;9(5):615-22
pubmed: 17383212
Science. 2011 Apr 1;332(6025):65-8
pubmed: 21350122
J Exp Med. 2009 Feb 16;206(2):299-311
pubmed: 19204111
Infect Immun. 2004 Aug;72(8):4878-80
pubmed: 15271952
AIDS. 1998 Nov 12;12(16):2227-8
pubmed: 9833866
J Antimicrob Chemother. 2018 Jan 01;73(1):151-155
pubmed: 29040636
JCI Insight. 2016 Aug 18;1(13):
pubmed: 27588307
PLoS One. 2016 Feb 05;11(2):e0145888
pubmed: 26849050
Methods Enzymol. 2005;391:314-29
pubmed: 15721389
Drug Dev Ind Pharm. 2019 Jun;45(6):869-881
pubmed: 30767577
Antimicrob Agents Chemother. 2002 Aug;46(8):2704-7
pubmed: 12121962
J Antimicrob Chemother. 2018 Aug 1;73(8):2089-2094
pubmed: 29788070
Curr Opin Investig Drugs. 2004 Feb;5(2):198-201
pubmed: 15043394
Antimicrob Agents Chemother. 2020 Sep 21;64(10):
pubmed: 32747357
J Innate Immun. 2011;3(2):180-99
pubmed: 21063074
Int J Pharm. 2021 Jun 15;603:120688
pubmed: 33965540
Antimicrob Agents Chemother. 2002 Mar;46(3):828-33
pubmed: 11850268
Cold Spring Harb Perspect Med. 2014 Jun 02;4(6):
pubmed: 24890837
J Antimicrob Chemother. 2007 Oct;60(4):889-92
pubmed: 17704513
Arthritis Rheum. 2010 Nov;62(11):3334-44
pubmed: 20662069
Sci Immunol. 2017 Nov 3;2(17):
pubmed: 29101209
Int Immunopharmacol. 2016 Nov;40:277-287
pubmed: 27639705
J Fungi (Basel). 2020 May 18;6(2):
pubmed: 32443486
Antimicrob Agents Chemother. 2000 Jun;44(6):1463-9
pubmed: 10817694
Antimicrob Agents Chemother. 2000 Sep;44(9):2356-60
pubmed: 10952579
Diagn Microbiol Infect Dis. 2008 Oct;62(2):182-5
pubmed: 18597968